Bristol Myers is cleaning up the post-Celgene merger pipeline, and they’re sweeping out an experimental checkpoint in the process
Back during the lead up to the $74 billion buyout of Celgene, the big biotech’s leadership did a little housecleaning with a major pact it had forged with Jounce. Out went the $2.6 billion deal and a collaboration on ICOS and PD-1.
Celgene, though, also added a $530 million deal — $50 million up front — to get the worldwide rights to JTX-8064, a drug that targets the LILRB2 receptor on macrophages.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 105,400+ biopharma pros reading Endpoints daily — and it's free.